View the website in Vertical mode on Mobile

Exel Way Pharma

Investing in a European medical start-up.

Exel Way Pharma is a Portuguese based cannabis company focused on industrial cultivation and production of medical grade cannabis (MGC) products and derivatives (i.e. cannabinoids, terpenes, etc.) in a wide range of levels and values.

Principal markets include the European Union and other continental European countries such as Switzerland, the United Kingdom, and Norway.


  • European market – forecasted addressable market of 10.2 million patients with a total market potential of USD 30+ billion by 2028.
  • Overall European market expected to have a compounded annual growth rate (CAGR) of 67.4% from 2022 onward.
  • Proprietary seed technology from Israel.
  • Clearly defined exit strategy.

Transformative investment designed to create a player ripe for acquisition by a strategic.

Project Team

Steven M. Pepa, Director → bio

Dr. Oded Sagee, Chief Science Officer → bio


See all Case Studies articles

No items found.